Endometrial cancer is no longer planned from stage alone. German university gynecologic-oncology centers publish pathways that combine histology, molecular risk classification, imaging, surgery, lymph-node assessment, radiotherapy and systemic treatment according to the individual risk profile. International patients should send the pathology and current staging evidence before asking for a surgical or medication quote because the correct treatment episode can differ substantially between early low-risk disease and aggressive, advanced or recurrent cancer.
Secure the tissue diagnosis before treatment planning
Heidelberg describes endometrial biopsy as the key diagnostic step when the uterine lining is suspicious, using an outpatient Pipelle biopsy in selected patients or curettage under anesthesia when appropriate. The pathology should define the histologic subtype and provide the basis for the next risk assessment.
Molecular classification now matters
Heidelberg states that endometrial cancer is divided into histologic and molecular subtypes and that this classification supports more individualized therapy. For an international second opinion, send any existing mismatch-repair, molecular or other pathology biomarker results together with the original pathology report.
Imaging and multidisciplinary review depend on the apparent extent of disease
Heidelberg documents vaginal ultrasound, tissue diagnosis and additional MRI or CT in selected patients, with findings discussed together with radiology, pathology, radiation oncology and the National Center for Tumor Diseases before treatment planning.
Hysterectomy is a central treatment for many operable cases
Heidelberg describes removal of the uterus as an important treatment component and notes that fallopian tubes and ovaries are often removed as well. The exact operation depends on stage, age, pathology and risk factors and should not be inferred from the word 'endometrial cancer' alone.
Minimally invasive and robotic surgery are access methods, not the indication
Heidelberg publishes laparoscopic and robot-assisted approaches for many patients. The decision should first establish the oncologic operation required; the surgical platform is then chosen according to anatomy, disease extent, previous surgery and patient factors.
Sentinel-node assessment can be part of surgical staging
Heidelberg lists sentinel-lymph-node assessment among its modern operative approaches. Whether sentinel mapping, more extensive nodal surgery or no nodal procedure is appropriate depends on stage, histology, molecular risk and the complete treatment plan.
Radiotherapy and systemic treatment depend on risk and stage
Heidelberg describes radiotherapy, chemotherapy and other systemic approaches for selected patients, particularly when recurrence risk is higher or disease is advanced. Its systemic-therapy information emphasizes histology, molecular risk subtype, stage and lymph-node status when deciding whether additional treatment is needed after surgery.
Mismatch-repair deficiency can influence advanced-treatment planning
Heidelberg specifically notes immunotherapy as an option in selected tumor profiles, including mismatch-repair-deficient disease. Medication choice changes with current evidence, approvals, prior therapy and tumor biology, so an up-to-date specialist review is more useful than a static drug list.
Consider hereditary risk when the pathology or family history suggests it
Charité operates a dedicated Lynch-syndrome service and notes the relationship between hereditary mismatch-repair defects and endometrial cancer. Ask whether the patient's age, tumor testing or family history indicates genetic counseling and whether existing molecular results are sufficient.
Records to send before travelling
A German gynecologic-oncology team should be able to determine diagnosis, molecular risk, stage and the intended treatment sequence from the submitted package.
- Endometrial biopsy or curettage pathology report
- Pathology slides or blocks if expert review is requested
- Molecular / mismatch-repair results when available
- Pelvic ultrasound, MRI or CT images in DICOM format
- Previous operative reports
- Radiotherapy or systemic-treatment history if already treated
- Relevant family cancer history and previous genetic testing
- Current medication and major medical conditions
- A clear question about surgery, sentinel nodes, adjuvant therapy, recurrence or second opinion
Sources and review
This guide was last source-reviewed on 2026-08-30.
- Endometrial cancer – molecular classification, diagnosis and treatment — Heidelberg University Hospital ↗
- Endometrial cancer – minimally invasive surgery and sentinel-node assessment — Heidelberg University Hospital ↗
- Systemic treatment and molecular risk — Heidelberg University Hospital ↗
- Gynecologic cancer center including ESGO Endometrial Cancer Center of Excellence — Charité – Universitätsmedizin Berlin ↗
- Lynch syndrome service — Charité – Universitätsmedizin Berlin ↗